Topical valrubicin application reduces skin inflammation in murine models.
Br J Dermatol
; 167(2): 288-95, 2012 Aug.
Article
en En
| MEDLINE
| ID: mdl-22458650
ABSTRACT
BACKGROUND:
Valrubicin is a cytostatic anthracycline analogue, lacking toxicity by skin and tissue contact, and represents a new drug with potential for topical treatment of psoriasis and nonmelanoma skin cancer (NMSC); the beneficial effects have been partly explained by its antiproliferative and proapoptotic characteristics.OBJECTIVES:
To assess the effect of valrubicin on skin inflammation as inflammation also plays a key role in psoriasis and NMSC.METHODS:
The effect of topical valrubicin treatment on skin inflammation in vivo was addressed in skin inflammation mouse models, where 12-O-tetradecanoylphorbol 13-acetate was used to induce irritant contact dermatitis. An acute and a chronic model were included, to investigate the effect of valrubicin in short-term inflammation and in more persistent inflammation. Inflammation-associated ear oedema was evaluated by measuring ear thickness, infiltration of neutrophil cells, and expression of inflammatory cytokines, interleukin (IL)-1ß and IL-6.RESULTS:
Topical valrubicin treatment effectively reduced the inflammatory response in the acute and the chronic models.CONCLUSIONS:
The present data document an anti-inflammatory effect of valrubicin, and may suggest an interesting new role for valrubicin in other debilitating skin diseases in which inflammation is a significant factor.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Doxorrubicina
/
Dermatitis Irritante
/
Antiinflamatorios
Tipo de estudio:
Prognostic_studies
Límite:
Animals
Idioma:
En
Año:
2012
Tipo del documento:
Article